Kyverna Therapeutics Inc (KYTX) — Titan Protect Analysis

KYTX

Kyverna Therapeutics Inc

Healthcare · ·

$7.47

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$486M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.71

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-74.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$32.00

+328% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Kyverna Therapeutics Inc

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product cand

https://kyvernatx.com

Country: United States Employees: 130 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.222

Positive but modest risk-adjusted returns

Kelly Fraction

0.0002

Marginal edge — very small allocation suggested

Calmar Ratio

-0.297

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-26.0%

Historical annualised return based on price data

Max Drawdown

-87.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.06

Significantly more volatile than the market

52W High

$13.67

45% below the year high

52W Low

$2.52

196% above the year low

Avg Volume

941,103

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.27

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

17.26

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-93,763,128

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-156,400,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$33.00

Target Median

$32.00

Target Low

$25.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go